Literature DB >> 4076051

The ovine bronchopulmonary lymph drainage pathways: a model to study pulmonary immune responses.

A D Chanana, D D Joel.   

Abstract

The lymph drainage pathways of all ovine bronchopulmonary segments (BPS) were traced following intrabronchial instillation of dyes and/or 125IUdR-labeled bacteria. The critical observation, relative to pulmonary immune apparatus, was the identification of at least three BPS-regional lymph node sets with nonoverlapping lymph drainage pathways: right cranial segment-cranial bronchial lymph node; left apical segment-caudal bronchial lymph node; and dorsal-basal, and accessory lobe segments-caudal mediastinal (caudal) lymph node. The efferent lymph drainage pathways from the pulmonary regional lymph nodes were also delineated. This anatomic information is being used to develop a model for studying the respective roles of intrapulmonary, regional, and systemic lymphoid tissues in pulmonary immune responsiveness.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4076051     DOI: 10.3109/01902148509057524

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  3 in total

1.  A Comparison of the Pharmacokinetics and Pulmonary Lymphatic Exposure of a Generation 4 PEGylated Dendrimer Following Intravenous and Aerosol Administration to Rats and Sheep.

Authors:  Gemma M Ryan; Robert J Bischof; Perenlei Enkhbaatar; Victoria M McLeod; Linda J Chan; Seth A Jones; David J Owen; Christopher J H Porter; Lisa M Kaminskas
Journal:  Pharm Res       Date:  2015-10-20       Impact factor: 4.200

2.  Distribution of lung-associated lymphocytes from the caudal mediastinal lymph node: effect of antigen.

Authors:  D D Joel; A D Chanana
Journal:  Immunology       Date:  1987-12       Impact factor: 7.397

3.  Liposomes are Poorly Absorbed via Lung Lymph After Inhaled Administration in Sheep.

Authors:  Jibriil P Ibrahim; Shadabul Haque; Robert J Bischof; Andrew K Whittaker; Michael R Whittaker; Lisa M Kaminskas
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.